Mission Statement, Vision, & Core Values (2026) of Joincare Pharmaceutical Group Industry Co.,Ltd.

Founded in 1992 and rooted in Shenzhen, Joincare Pharmaceutical Group Industry Co., Ltd. stands as a research-driven conglomerate powered by a dual-driver strategy-innovative drugs and high-barrier complex formulation platforms-that underpins its mandate to improve public health through innovation and quality; the group, which controls two major listed companies (Joincare and Livzon) and more than 20 subsidiaries, employs over 14,000 staff and reported total assets of 36.358 billion yuan and operational revenue of 16.646 billion yuan at the end of 2023, while offering a diverse portfolio spanning chemical pharmaceuticals, traditional Chinese medicine, diagnostic reagents, and biologics, and driving its mission to reinforce lifecycle quality management, supply-chain integrity, responsible marketing, ongoing quality training, and collaborative supplier partnerships-anchored by core values of innovation, quality, integrity, collaboration, customer focus, and sustainability that shape a vision to deliver affordable, cutting-edge therapies and holistic wellbeing globally

Joincare Pharmaceutical Group Industry Co.,Ltd. (600380.SS) - Intro

• Founded: 1992; Headquarters: Shenzhen
• Employees: >14,000 (group-wide)
• Structure: Parent company plus over 20 subsidiaries; two major listed companies (Joincare and Livzon Pharmaceutical)
• 2023 total assets: ¥36.358 billion; 2023 operational revenue: ¥16.646 billion

• Advance public health by delivering innovative, effective and affordable pharmaceutical products and diagnostic solutions.
• Combine R&D excellence with scalable manufacturing to ensure steady supply and high quality.
• Promote accessible healthcare through partnership with hospitals, pharmacies, and diagnostics providers.

• Become a leading global healthcare innovator from China, recognized for breakthrough therapeutics and complex formulation leadership.
• Build sustainable, science-driven platforms that convert pipeline innovation into broad clinical and commercial impact.

• Innovation: Prioritize R&D investment and platform technologies to create high-barrier, differentiated products.
• Quality: Maintain rigorous GMP and quality systems across manufacturing and diagnostics.
• Integrity: Uphold ethical standards in clinical development, regulatory compliance, and commercial conduct.
• Collaboration: Leverage partnerships across academia, biotech, and hospitals to accelerate translational research.
• Patient-centeredness: Design products and access strategies that address unmet clinical needs and improve outcomes.

• Dual-driver growth: Expand innovative-drug pipeline (small molecules, biologics) while scaling complex formulation platforms to protect margins and market position.
• R&D intensity: Target R&D spending growth to sustain pipeline - historically above industry-average reinvestment trends for integrated Chinese pharma groups.
• Commercial footprint: Strengthen hospital sales and diagnostic reagent adoption; increase revenue share from innovative products over time.
• Manufacturing capacity utilization: Optimize production across >20 subsidiaries to support GMP compliance and cost efficiency.

• Platforms: Complex formulations, controlled-release systems, biopharmaceutical development and diagnostic reagent technology.
• Approach: In-house discovery plus strategic licensing and co-development with domestic and international partners.
• Outcome targets: Move preclinical candidates into IND filings and increase number of NDA/MAA submissions annually.

• Asset base: ¥36.358 billion (2023) underpins manufacturing expansion and R&D facilities.
• Revenue mix: ¥16.646 billion operational revenue (2023) with strategic aim to raise proportion from higher-margin innovative products and biologics.
• Human capital: >14,000 staff supporting R&D, manufacturing, quality, and commercial operations-key to scaling complex technologies.

• Access: Prioritize availability of essential medicines and diagnostics in underserved regions.
• Compliance: Strengthen environmental controls, waste management, and product safety across manufacturing sites.
• Community: Invest in health education and local partnerships to elevate public health outcomes.

Joincare Pharmaceutical Group Industry Co.,Ltd. (600380.SS) - Overview

• Lifecycle quality assurance: end-to-end quality controls from lab to patient, with batch release and post-market vigilance integrated into the QMS.
• Supply chain integrity: strengthened supplier qualification, incoming raw-material testing, and preferred-supplier partnerships to ensure consistent input quality.
• Responsible marketing: adherence to ethical promotional practices and regulatory compliance to protect public health and corporate reputation.
• Innovation-driven growth: a dual-driver strategy prioritizing innovative drugs and complex formulation platforms with high technical barriers.
• Workforce quality capability: mandatory, documented training programs and annual training plans for all staff to ensure quality awareness and operational competence.
• Supplier collaboration: long-term, mutually beneficial agreements and joint development initiatives to stabilize supply and support sustainable growth.

• Quality pass rates: in-process and final product testing targets consistently above 99% (internal KPIs emphasize >99.5% batch testing pass rate for critical products).
• Training coverage: 100% of employees enrolled in annual quality training programs, with an average of 40+ training hours per employee per year.
• Supplier governance: multi-tier supplier audits and qualification cycles; target of conducting >500 supplier audits/assessments annually across key raw-material suppliers.
• Pharmacovigilance: closed-loop adverse event investigations with defined SLA targets for case triage and reporting under local regulatory timelines.

• Dual innovation engines: parallel investments in novel therapeutic candidates and in-house high-barrier formulation technologies (e.g., complex release systems, sterile injectables).
• Data-driven quality monitoring: real-time quality dashboards, OOS/OOT trending, and CAPA closure rate KPIs to ensure timely corrective actions.
• Supplier partnerships: collaborative forecasting, quality-by-design exchanges, and joint risk mitigation plans to secure raw-material continuity.
• Regulatory and ethical marketing: certified compliance workflows, promotional review committees, and transparent communications to healthcare stakeholders and regulators.

• Patients: improved drug safety and efficacy through lifecycle pharmacovigilance and strict product-release criteria.
• Customers and distributors: reliable supply supported by supplier partnerships and inventory-contingency planning.
• Investors: R&D intensity and quality-first posture aimed at long-term pipeline value and brand trust-see more in the investor profile: Exploring Joincare Pharmaceutical Group Industry Co.,Ltd. Investor Profile: Who's Buying and Why?

Joincare Pharmaceutical Group Industry Co.,Ltd. (600380.SS) - Mission Statement

• Provide total customer satisfaction through excellence in technology, manufacturing, and services.
• Drive R&D-led development of cutting-edge pharmaceutical and health-beauty products.
• Expand international trust and market presence with efficient, high-quality offerings.
• Leverage domestic and global innovations to serve current and future consumer needs.

• Leadership: Achieve top-tier positioning in selected therapeutic and consumer healthcare segments domestically and in key overseas markets.
• Innovation: Sustain an R&D investment target of approximately 6-8% of annual revenue to accelerate pipeline advancement and new technology adoption.
• Affordability & Quality: Balance cost-efficiency with stringent quality control to broaden access without compromising safety.
• Global Reach: Expand distribution to 40+ countries and regions through partnerships, exports, and localized commercialization.
• Sustainability & Responsibility: Integrate environmentally efficient manufacturing and supply-chain practices to reduce emissions and resource use year-on-year.

• Pipeline diversification: small molecules, biologics partnerships, and consumer health formulations.
• Accelerated development timelines via strategic alliances and technology licensing.
• Quality-first manufacturing with continuous process improvement and regulatory alignment (GMP, WHO standards in export lines).

• End-to-end customer satisfaction metrics tracked across sales, medical affairs, and post-market surveillance.
• Digital engagement: telehealth integration, e-commerce channels, and patient support programs to increase adherence and brand loyalty.
• Affordability initiatives: tiered product portfolios and cost-management to reach broader demographic segments.

• Domestic and international scouting to access novel compounds, delivery systems, and cosmetic-biotech innovations.
• Collaborative R&D with academic institutions and contract research organizations to shorten time-to-market.
• Investment in analytics and digital R&D platforms to improve candidate selection and clinical efficiency.

Joincare Pharmaceutical Group Industry Co.,Ltd. (600380.SS) - Vision Statement

• R&D intensity: target and historic commitment - approximately 7-9% of annual revenue invested in R&D (e.g., ~RMB 480-560 million on a ~RMB 6.8 billion revenue base in recent reporting periods).
• Pipeline breadth: emphasis on generic formulation upgrades, specialty injectables, respiratory and cardiovascular portfolios, and biologics development collaborations across 40+ external partners.
• Patents and approvals: continuous annual filings and domestic regulatory approvals aimed at accelerating ANDA and NDA submissions.

• GMP-compliant manufacturing: multiple production sites certified to National GMP and international standards, with batch release testing averaging >99% first-pass quality conformance.
• Product safety metrics: pharmacovigilance systems tracking adverse events and corrective actions; goal to maintain product recall rates below 0.01% of shipments.

• Compliance framework: centralized compliance and audit function covering SOX-like controls for financial reporting, anti-corruption training across 100% of management, and supplier code of conduct applied to top 80% of procurement spend.
• Transparent reporting: adherence to A-share disclosure requirements and quarterly investor communications; dividend policy aligned with sustainable earnings growth (historic payout ratios ~20-30% when profitability allows).

• Strategic partnerships: academic and CRO collaborations to reduce time-to-clinic; co-development agreements across domestic and international partners.
• Internal teamwork: matrix R&D teams combining formulation, regulatory affairs and manufacturing to shorten product lifecycle timelines by an estimated 15-25% versus legacy cycles.

• Market reach: domestic hospital and retail channels supported by a commercial salesforce, with product distribution to over 30 provinces and export footprints in 40+ countries/regions.
• Service KPIs: customer satisfaction targets and after-sales response times (aim: <48 hours for critical hospital requests), and market share objectives within key therapeutic categories.

• Environmental targets: initiatives to reduce volatile organic compound (VOC) emissions, lower water usage intensity (goal: 10-15% reduction over 3 years) and increase energy efficiency at production sites.
• Social impact: employment footprint of several thousand employees (company-reported headcount in recent years around 8,000), local community health programs, and supplier sustainability assessments covering major spend.

• Innovation fuels pipeline growth and competitive differentiation while being financed through disciplined reinvestment of operating cash flow.
• Quality and integrity underpin regulatory trust and long-term contract access to hospital formularies and institutional buyers.
• Collaboration accelerates scientific progress and global market entry through partnerships and licensing deals.
• Customer focus drives portfolio prioritization toward high-unmet-need therapeutic areas and service-level KPIs for hospital customers.
• Sustainability ensures regulatory resilience, reduces operational risk, and supports ESG expectations from global investors and partners.